Journal: Current Cancer Drug Targets
Guest editor(s):Dr. Yuan Qin
Co-Guest Editor(s):

Introduction

Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. Based on the close relationship between inflammation and cancer progression, targeting inflammation is an important way for improving anti-cancer treatment. A better understanding of the relationship between the dysregulated inflammation and cancer progression would be conducive toward the development of new strategies for combating cancer, and would enhance the efficacy of immunotherapy, chemo- or radiotherapeutic approaches. By reshaping the tumor immune microenvironment (TIME), it is expected to realize the innovation of the new generation of tumor precision medicine. The goal of this Thematic Issue is to provide a forum to advance research on reshaping the TIME: drugs with better penetration and targeting capabilities, drug delivery systems with higher stability, reasonable joint schemes, quick and low-cost individual detection methods in basic research and clinical practice are all helpful for us to win the war against malignant tumor.

Keywords

tumor immune microenvironment, malignant tumor, inflammation, immunotherapy, small molecules, biomacromolecules, drug delivery systems, individual detection methods

Sub-topics

1.Novel mechanisms that reshaping TIME in basic research.
2.Novel combined therapy that reshaping TIME in clinical practice.
3.Small Molecules targeting TIME.
4.Antibodies and other biomacromolecules targeting TIME.
5.Immune cell therapies targeting TIME.
6.Drug delivery systems targeting TIME.
7.Novel individual detection methods on TIME.